FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W95961711> ?p ?o ?g. }

• W95961711 abstract "The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear.To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes.Multicenter, parallel-group, double-blind, randomized controlled trial.Academic movement disorders clinics at 22 sites in the United States and Canada.Patients with early Parkinson disease (N = 301) who required dopaminergic therapy to treat emerging disability, enrolled between October 1996 and August 1997 and observed until August 2001.Subjects were randomly assigned to receive 0.5 mg of pramipexole 3 times per day with levodopa placebo (n = 151) or 25/100 mg of carbidopa/levodopa 3 times per day with pramipexole placebo (n = 150). Dosage was escalated during the first 10 weeks for patients with ongoing disability. Thereafter, investigators were permitted to add open-label levodopa or other antiparkinsonian medications to treat ongoing or emerging disability.Time to the first occurrence of dopaminergic complications: wearing off, dyskinesias, on-off fluctuations, and freezing; changes in the Unified Parkinson's Disease Rating Scale and quality-of-life scales; and adverse events.Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias (24.5% vs 54%; hazard ratio, 0.37; 95% confidence interval [CI], 0.25-0.56; P<.001) and wearing off (47% vs 62.7%; hazard ratio, 0.68; 95% CI, 0.49-0.63; P =.02). Initial levodopa treatment resulted in a significant reduction in the risk of freezing (25.3% vs 37.1%; hazard ratio, 1.7; 95% CI, 1.11-2.59; P =.01). By 48 months, the occurrence of disabling dyskinesias was uncommon and did not significantly differ between the 2 groups. The mean improvement in the total Unified Parkinson's Disease Rating Scale score from baseline to 48 months was greater in the levodopa group than in the pramipexole group (2 +/- 15.4 points vs -3.2 +/- 17.3 points, P =.003). Somnolence (36% vs 21%, P =.005) and edema (42% vs 15%, P<.001) were more common in pramipexole-treated subjects than in levodopa-treated subjects. Mean changes in quality-of-life scores did not differ between the groups.Initial treatment with pramipexole resulted in lower incidences of dyskinesias and wearing off compared with initial treatment with levodopa. Initial treatment with levodopa resulted in lower incidences of freezing, somnolence, and edema and provided for better symptomatic control, as measured by the Unified Parkinson's Disease Rating Scale, compared with initial treatment with pramipexole. Both options resulted in similar quality of life. Levodopa and pramipexole both appear to be reasonable options as initial dopaminergic therapy for Parkinson disease, but they are associated with different efficacy and adverse-effect profiles." @default.
• W95961711 created "2016-06-24" @default.
• W95961711 creator A5000106307 @default.
• W95961711 creator A5000332964 @default.
• W95961711 creator A5003201365 @default.
• W95961711 creator A5003626387 @default.
• W95961711 creator A5005433518 @default.
• W95961711 creator A5009117789 @default.
• W95961711 creator A5009415772 @default.
• W95961711 creator A5010642600 @default.
• W95961711 creator A5011859533 @default.
• W95961711 creator A5013890564 @default.
• W95961711 creator A5014852142 @default.
• W95961711 creator A5015140945 @default.
• W95961711 creator A5015466028 @default.
• W95961711 creator A5017122855 @default.
• W95961711 creator A5017246900 @default.
• W95961711 creator A5018824082 @default.
• W95961711 creator A5019796476 @default.
• W95961711 creator A5025542658 @default.
• W95961711 creator A5026525409 @default.
• W95961711 creator A5027165894 @default.
• W95961711 creator A5027204183 @default.
• W95961711 creator A5027468065 @default.
• W95961711 creator A5029815425 @default.
• W95961711 creator A5034197012 @default.
• W95961711 creator A5034630981 @default.
• W95961711 creator A5036528727 @default.
• W95961711 creator A5037230816 @default.
• W95961711 creator A5038254974 @default.
• W95961711 creator A5038389802 @default.
• W95961711 creator A5038961732 @default.
• W95961711 creator A5039686012 @default.
• W95961711 creator A5040466491 @default.
• W95961711 creator A5044017133 @default.
• W95961711 creator A5045171661 @default.
• W95961711 creator A5047478917 @default.
• W95961711 creator A5047500033 @default.
• W95961711 creator A5049841206 @default.
• W95961711 creator A5051674393 @default.
• W95961711 creator A5052099324 @default.
• W95961711 creator A5052985748 @default.
• W95961711 creator A5054236844 @default.
• W95961711 creator A5054911069 @default.
• W95961711 creator A5056904072 @default.
• W95961711 creator A5057891824 @default.
• W95961711 creator A5059928924 @default.
• W95961711 creator A5060095007 @default.
• W95961711 creator A5065068523 @default.
• W95961711 creator A5068655451 @default.
• W95961711 creator A5070919684 @default.
• W95961711 creator A5071000356 @default.
• W95961711 creator A5072919987 @default.
• W95961711 creator A5073135069 @default.
• W95961711 creator A5073744063 @default.
• W95961711 creator A5074151067 @default.
• W95961711 creator A5076341883 @default.
• W95961711 creator A5076725742 @default.
• W95961711 creator A5076922088 @default.
• W95961711 creator A5077781946 @default.
• W95961711 creator A5078053771 @default.
• W95961711 creator A5078767342 @default.
• W95961711 creator A5079294050 @default.
• W95961711 creator A5079517130 @default.
• W95961711 creator A5082224769 @default.
• W95961711 creator A5082387696 @default.
• W95961711 creator A5084487682 @default.
• W95961711 creator A5088389666 @default.
• W95961711 creator A5088428806 @default.
• W95961711 creator A5089460389 @default.
• W95961711 creator A5091189781 @default.
• W95961711 date "2004-07-01" @default.
• W95961711 modified "2023-10-16" @default.
• W95961711 title "Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease" @default.
• W95961711 cites W133512341 @default.
• W95961711 cites W1984839231 @default.
• W95961711 cites W2015749893 @default.
• W95961711 cites W2064996887 @default.
• W95961711 cites W2068817959 @default.
• W95961711 cites W2135444901 @default.
• W95961711 cites W2152111408 @default.
• W95961711 cites W2321678632 @default.
• W95961711 cites W2322912881 @default.
• W95961711 cites W2473786944 @default.
• W95961711 cites W2563241409 @default.
• W95961711 cites W2796700885 @default.
• W95961711 doi "https://doi.org/10.1001/archneur.61.7.1044" @default.
• W95961711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15262734" @default.
• W95961711 hasPublicationYear "2004" @default.
• W95961711 type Work @default.
• W95961711 sameAs 95961711 @default.
• W95961711 citedByCount "308" @default.
• W95961711 countsByYear W959617112012 @default.
• W95961711 countsByYear W959617112013 @default.
• W95961711 countsByYear W959617112014 @default.
• W95961711 countsByYear W959617112015 @default.
• W95961711 countsByYear W959617112016 @default.
• W95961711 countsByYear W959617112017 @default.
• W95961711 countsByYear W959617112018 @default.
• W95961711 countsByYear W959617112019 @default.

• next